Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $481.00M | $376.71M | $451.77M | $354.26M | $325.72M | $264.86M | $298.01M | $290.08M |
| Cost of revenue | $79.17M | $79.24M | $78.77M | $55.24M | $46.36M | $48.40M | $42.06M | $49.43M |
| Gross profit | $401.83M | $297.47M | $373.00M | $299.02M | $279.36M | $216.46M | $255.95M | $240.66M |
| Gross margin | 83.5% | 79.0% | 82.6% | 84.4% | 85.8% | 81.7% | 85.9% | 83.0% |
| Research and development | $27.66M | $25.56M | $31.90M | $17.25M | $17.54M | $14.80M | $20.44M | $18.46M |
| Selling, general and administrative | $57.00M | $57.88M | $77.03M | $46.09M | $41.61M | $42.36M | $42.25M | $41.24M |
| Operating expenses | $114.17M | $112.95M | $417.19M | $81.10M | $76.92M | $74.92M | $80.45M | $77.46M |
| Operating income | $287.65M | $184.52M | −$44.19M | $217.92M | $202.44M | $141.54M | $175.50M | $163.20M |
| Operating margin | 59.8% | 49.0% | -9.8% | 61.5% | 62.2% | 53.4% | 58.9% | 56.3% |
| EBITDA | $321.62M | $218.25M | $267.38M | $238.34M | $222.94M | $161.98M | $195.92M | $181.88M |
| Interest income | $2.84M | $0 | $0 | — | $6.89M | $0 | $0 | — |
| Interest expense | −$5.59M | −$5.51M | −$4.91M | −$4.30M | −$4.39M | −$4.53M | −$4.54M | −$4.52M |
| Income before taxes | $284.90M | $180.33M | −$100.85M | $218.96M | $204.94M | $143.83M | $178.21M | $165.15M |
| Income taxes | $54.99M | $30.28M | $40.74M | $43.73M | $39.78M | $25.73M | $41.20M | $28.14M |
| Net income | $229.91M | $150.05M | −$141.59M | $175.23M | $165.16M | $118.10M | $137.01M | $137.01M |
| Net margin | 47.8% | 39.8% | -31.3% | 49.5% | 50.7% | 44.6% | 46.0% | 47.2% |
| EPS, basic | $1.96 | $1.27 | −$1.20 | $1.49 | $1.36 | $0.96 | $1.08 | $1.08 |
| EPS, diluted | $1.90 | $1.22 | −$1.16 | $1.43 | $1.33 | $0.93 | $1.06 | $1.05 |
| Diluted shares | 121.22M | 122.88M | 122.48M | 122.33M | 124.16M | 126.64M | 129.45M | 130.13M |
Figures describe Halozyme Therapeutics shares, not any token. As of Aug 6, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.